scholarly journals Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion

Cancer ◽  
2006 ◽  
Vol 106 (9) ◽  
pp. 1990-1997 ◽  
Author(s):  
Shuntaro Obi ◽  
Haruhiko Yoshida ◽  
Risa Toune ◽  
Tadao Unuma ◽  
Miho Kanda ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Interferon Alpha ◽  
Venous Invasion ◽  
Advanced Hepatocellular Carcinoma

Combination Therapy with S-1 and Pegylated Interferon Alpha for Advanced Hepatocellular Carcinoma

Oncology ◽  
2008 ◽  
Vol 75 (1) ◽  
pp. 106-113 ◽  
Author(s):  
Kazuomi Ueshima ◽  
Masatoshi Kudo ◽  
Tomoyuki Nagai ◽  
Chie Tatsumi ◽  
Taisuke Ueda ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Interferon Alpha ◽  
Pegylated Interferon ◽  
Advanced Hepatocellular Carcinoma ◽  
Pegylated Interferon Alpha

scholarly journals The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study

2018 ◽  
Vol 57 (10) ◽  
pp. 1345-1353 ◽  
Author(s):  
Yoshiyuki Wada ◽  
Yuko Takami ◽  
Hajime Matsushima ◽  
Masaki Tateishi ◽  
Tomoki Ryu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Retrospective Study ◽  
Combination Therapy ◽  
Advanced Hepatocellular Carcinoma ◽  
Safety And Efficacy

scholarly journals Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma

2020 ◽  
Vol 14 (2) ◽  
pp. 367-372 ◽  
Author(s):  
Tsai-Hung Yen ◽  
Chung-Hsin Chang ◽  
Sz-Iuan  Shiu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Tumor Lysis Syndrome ◽  
Tumor Burden ◽  
Therapeutic Interventions ◽  
Advanced Hepatocellular Carcinoma ◽  
Large Tumor ◽  
Tumor Lysis ◽  
Advanced Hcc ◽  
First Case

Tumor lysis syndrome (TLS) is a life-threatening emergency that usually develops in rapidly proliferating hematologic malignancies or advanced solid tumor following cytotoxic chemotherapy or therapeutic interventions. TLS is especially rare in patients with hepatocellular carcinoma (HCC). Therefore, we present a case of a female patient with newly diagnosed advanced HCC who developed TLS and hepatic failure after receiving combination therapy of nivolumab and sorafenib. To our knowledge, this is the first case of TLS in a patient with advanced HCC owing to combination therapy of nivolumab and sorafenib. We also reviewed the literature and summarized the characteristics of TLS in patients with advanced HCC receiving various therapeutic interventions. The overall mortality rate was 63% and regarding the management, transarterial chemoembolization (TACE) was the most common etiology. TACE-related TLS developed more rapidly than sorafenib-related TLS. Furthermore, the efficacy and safety of combination therapy of nivolumab and sorafenib should be further evaluated, and TLS should still be a concern, especially in patients with large tumor burden.

Sign in / Sign up

Export Citation Format

Share Document